Using a new method to deliver neuroprotective antibodies for Alzheimer's disease treatment
CD98hc Brain Shuttles for Delivering Off-the-shelf Neuroprotective Antibodies in Alzheimer's Disease
['FUNDING_R01'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-11009966
This study is looking at a new way to help deliver special antibodies to the brain for people with Alzheimer's disease, using a clever method to get past a barrier that usually keeps treatments out, and it will also see how age and the disease itself affect this process in mice.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-11009966 on ClinicalTrials.gov |
What this research studies
This research focuses on improving the delivery of neuroprotective antibodies to the brain for patients with Alzheimer's disease. The team is developing a bispecific antibody shuttle that can effectively cross the blood-brain barrier, which is a significant challenge in treating this condition. By targeting a specific receptor, CD98hc, the researchers aim to enhance the transport of these antibodies into the brain, potentially leading to better therapeutic outcomes. The study will evaluate how age and disease impact this transport mechanism and will test the effectiveness of this approach in a mouse model of Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults, particularly those aged 65 and above, who are experiencing symptoms of Alzheimer's disease.
Not a fit: Patients under the age of 65 or those without Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Alzheimer's disease by improving the delivery of therapeutic antibodies to the brain.
How similar studies have performed: While the approach of using bispecific antibody shuttles is innovative, previous research has shown promise in similar strategies for enhancing drug delivery across the blood-brain barrier.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TESSIER, PETER M — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: TESSIER, PETER M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.